“GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company’s first doublet has performed modestly on the market compared to a key rival’s three-drug regimen.”
For more, click here.